Greenlane To Distribute Vaporization Brand AUXO By CCELL Via New Partnership

Greenlane Holdings, Inc. (NASDAQ: GNLN) announced on Thursday its distribution partnership with AUXO, an innovative vaporization brand produced by SMOORE.

Greenlane Holdings, Inc. (NASDAQ:GNLN) announced on Thursday its distribution partnership with AUXO, an innovative vaporization brand produced by SMOORE.

AUXO is a consumer-focused product line backed by CCELL patented technology, world-class research, and a high standard of manufacturing. Included in the AUXO product catalog are premium dry herb, concentrate, and dual-use vaporizers, many of which are compatible with the AUXO Connect App to personalize sessions.

“Greenlane’s strategic partnership to distribute the consumer-facing AUXO brand is another example of how we are implementing our business strategy to focus on both high-margin house brands and strategic partnerships,” Craig Snyder, president of Greenlane, said. “We are excited about this new line of innovative vaporization products and believe it will contribute toward Greenlane’s growth and success.”

Why It Matters

Brad Li, global chief commercial officer of CCELL and AUXO said that the new collaboration expands SMOORE’s portfolio of consumer-facing brands into new channels.

“The partnership will also bring more synergy to CCELL’s B2B endeavors, and we believe this is one of many future growth opportunities to deliver exceptional value to consumers,” Li said.

  • Greenlane Picks Craig Snyder To Take The Helm As CEO Next Year
  • Greenlane Q2 Revenue Grows 15% YoY, Provides Outlook
  • Greenlane Secure $15M Accreditive Credit Facility
  • Greenlane Secures $15 Million Asset-Based Loan

Price Action

Greenlane’s shares traded 4.9938% lower at $1.5201 per share at the time of writing on Thursday morning.

Photo: Courtesy of Chiara Summer on Unsplash

Total
0
Shares
Related Posts
Read More

Why Jaguar Health Stock Is Up Today

Jaguar Health shares are trading higher Tuesday after the company announced it has signed an exclusive 5-year in-license agreement with Venture Life Group. The license agreement is for the U.S. market for Venture Life's FDA-approved prescription product, Gelclair. Gelclair is for the treatment of oral mucositis, also called "chemo mouth." "We are very happy to have executed the in-license agreement for Gelclair - and thus to have initiated Jaguar's commercial footprint in our core focus area of cancer supportive care," said Lisa Conte, Jaguar's president and CEO.

JAGX